PHYSEO Pharmacology 2020

Section I – Cyclosporine

Section II – Tacrolimus

Section III – Sirolimus 

Section IV – Basiliximab 

Section V – Azathioprine and 6 MP

Section VI – Mycophenolate

Section VII – Glucocorticoids

Section VIII – Bone Marrow Stimulation

Section IX – Interferons Alpha, Beta and Gamma

Section I – Oseltamivir and Zanamivir

Section II – Acyclovir, Valacyclovir, and Famciclovir

Section III – Ganciclovir and Valganciclovir

Section IV – Foscarnet and Cidofovir

Section V – NRTIs

Section VI – NNRTIs

Section VII – Protease Inhibitors

Section VIII – Integrase Inhibitors

Section IX – Fusion Inhibitors 

Section X – Hepatitis C Therapy

Section I – Malathion, Permethrin, and Lindane

Section I – Amphotericin B, Nystatin, and Flucytosine

Section II – Azoles

Section III – Terbinafine

Section IV – Echinocandins

Section V – Griseofulvin

Section I – Penicillin G,V

Section II – Amoxicillin and Ampicillin

Section III – Antistaphylococcal Penicillins

Section IV – Antipseudomonal Penicillins

Section V – Cephalosporins

Section VI – Carbapenems

Section VII – Monobactams 

Section VIII – Vancomycin

Section IX – Bacitracin

Section X – Aminoglycosides

Section XI – Tetracyclines

Section XII – Glycylcyclines

Section XIII – Chloramphenicol

Section XIV – Clindamycin

Section XV – Linezolid

Section XVI – Macrolides

Section XVII – Polymyxins

Section XVIII – Trimethoprim and Sulfonamides

Section XIX – Fluoroquinolones

Section XX – Daptomycin

Section XXI – Metronidazole

Section XXII – Dapsone, Rifamycins, Clofazimine (Leprosy Drugs)

Section XXIII – Isoniazid (RIPE)

Section XXIV – Ethambutol and Pyrazinamide

Section I – Mannitol

Section II – Acetazolamide 

Section III – Loop Diuretics and Ethacrynic Acid 

Section IX – Thiazide Diuretics 

Section XI – ACE Inhibitors

Section XII – Angiotensin II Receptor Blockers 

Section XIII – Aliskiren